John Wilton Sells 17,574 Shares of Auna (NYSE:AUNA) Stock

Auna S.A. (NYSE:AUNAGet Free Report) Director John Wilton sold 17,574 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.17, for a total transaction of $73,283.58. Following the transaction, the director owned 49,974 shares of the company’s stock, valued at approximately $208,391.58. This represents a 26.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Auna Stock Performance

Shares of NYSE AUNA opened at $4.52 on Wednesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.00 and a current ratio of 1.09. The company has a market cap of $334.16 million, a P/E ratio of 17.37 and a beta of 0.81. The firm’s fifty day moving average is $5.20 and its two-hundred day moving average is $5.01. Auna S.A. has a 52-week low of $4.09 and a 52-week high of $6.85.

Auna (NYSE:AUNAGet Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.14). The company had revenue of $336.84 million for the quarter, compared to the consensus estimate of $320.54 million. Auna had a net margin of 1.53% and a return on equity of 16.25%. As a group, analysts anticipate that Auna S.A. will post 0.81 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wall Street Zen lowered Auna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. reduced their price objective on Auna from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Auna in a report on Friday, March 27th. Finally, Zacks Research downgraded Auna from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Auna presently has a consensus rating of “Hold” and an average target price of $6.97.

Read Our Latest Stock Analysis on AUNA

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in Auna by 487.7% in the first quarter. Renaissance Technologies LLC now owns 668,457 shares of the company’s stock worth $3,683,000 after acquiring an additional 554,707 shares in the last quarter. Marshall Wace LLP raised its position in Auna by 391.0% during the fourth quarter. Marshall Wace LLP now owns 162,992 shares of the company’s stock valued at $802,000 after purchasing an additional 129,799 shares during the period. Lazard Asset Management LLC purchased a new stake in Auna during the first quarter valued at approximately $557,000. Goldman Sachs Group Inc. lifted its stake in shares of Auna by 43.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 71,645 shares of the company’s stock valued at $352,000 after purchasing an additional 21,579 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Auna in the 1st quarter worth approximately $324,000.

Auna Company Profile

(Get Free Report)

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.

Further Reading

Receive News & Ratings for Auna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auna and related companies with MarketBeat.com's FREE daily email newsletter.